Idenix sees promise for anti-HCV regimen

Massachusetts, USA-based biopharmaceutical company Idenix Pharmaceuticals says that the results from a Phase II study, designed to evaluate its combination hepatitis C therapy, indicate that the treatment may cut virus levels, following assessment using the polymerase chain reaction. The trial examined Idenix' lead drug candidate valopicitabine, in combination with pegylated interferon and ribavirnin in patients infected with the genotype-1 strain of the virus.

The results indicate that there was no pharmacokinetic or pharmacodynamic drug-drug interaction between the two principal components. The trial also revealed that the combination has satisfactory tolerability.